share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股SEC公告 ·  2024/07/26 21:08

牛牛AI助理已提取核心訊息

iBio has entered into an amended employment agreement with CEO and CSO Martin Brenner, effective July 1, 2024. The agreement sets Brenner's base salary at $522,365 and increases his bonus target to 50% of base salary for fiscal year 2025, while maintaining the 40% target for fiscal year 2024. The agreement includes standard benefits and participation in the company's executive officer benefit plans.The updated agreement outlines enhanced severance provisions. In case of termination without cause or resignation for good reason, Brenner will receive 12 months of base salary, pro-rated bonus, and 12 months of COBRA coverage. If such termination occurs around a Sale Event, benefits increase to 18 months of salary, target bonus payment, accelerated equity vesting, and 18 months of COBRA coverage.The agreement includes standard intellectual property assignment provisions and non-solicitation terms. All severance payments are contingent upon executing a general release of claims, maintaining Brenner's "at will" employment status.
iBio has entered into an amended employment agreement with CEO and CSO Martin Brenner, effective July 1, 2024. The agreement sets Brenner's base salary at $522,365 and increases his bonus target to 50% of base salary for fiscal year 2025, while maintaining the 40% target for fiscal year 2024. The agreement includes standard benefits and participation in the company's executive officer benefit plans.The updated agreement outlines enhanced severance provisions. In case of termination without cause or resignation for good reason, Brenner will receive 12 months of base salary, pro-rated bonus, and 12 months of COBRA coverage. If such termination occurs around a Sale Event, benefits increase to 18 months of salary, target bonus payment, accelerated equity vesting, and 18 months of COBRA coverage.The agreement includes standard intellectual property assignment provisions and non-solicitation terms. All severance payments are contingent upon executing a general release of claims, maintaining Brenner's "at will" employment status.
iBio與首席執行官兼首席科學官馬丁·布倫納簽署了一份修訂的僱傭協議,該協議自2024年7月1日起生效。該協議將布倫納的基本工資定在522,365美元,並將他的獎金目標提高到2025財政年度基本工資的50%,同時維持2024財政年度的40%目標。該協議包括標準福利和參與公司高管福利計劃。更新後的協議概述了增強的離職條款。如果因非過失解僱或因合理原因辭職,布倫納將獲得12個月的基本工資、按比例計算的獎金和12個月的COBRA保險。若在出售事件附近發生此類解僱,福利將增加至18個月的工資、目標獎金支付、加速股權歸屬和18個月的COBRA保險。該協議包括標準的知識產權轉讓條款和非招攬條款。所有離職付款均需在執行一般索賠放棄協議、維持布倫納的「隨時」僱傭狀態後進行。
iBio與首席執行官兼首席科學官馬丁·布倫納簽署了一份修訂的僱傭協議,該協議自2024年7月1日起生效。該協議將布倫納的基本工資定在522,365美元,並將他的獎金目標提高到2025財政年度基本工資的50%,同時維持2024財政年度的40%目標。該協議包括標準福利和參與公司高管福利計劃。更新後的協議概述了增強的離職條款。如果因非過失解僱或因合理原因辭職,布倫納將獲得12個月的基本工資、按比例計算的獎金和12個月的COBRA保險。若在出售事件附近發生此類解僱,福利將增加至18個月的工資、目標獎金支付、加速股權歸屬和18個月的COBRA保險。該協議包括標準的知識產權轉讓條款和非招攬條款。所有離職付款均需在執行一般索賠放棄協議、維持布倫納的「隨時」僱傭狀態後進行。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。